Latest Therapeutics News

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting genetic diseases, alongside a strong cash runway supporting ongoing development.

Actinogen Medical has fast-tracked enrolment in its pivotal Alzheimer’s trial, secured a clear FDA regulatory path, and strengthened its financial position with funding extending its runway to mid-2026.

Avecho Biotechnology has raised $2.5 million from institutional investors to fast-track manufacturing and regulatory preparations for its CBD TPM capsule amid ongoing Phase III trials.

Starpharma has secured a $5.5 million upfront payment from Genentech as part of a new collaboration to develop dendrimer-drug conjugates targeting cancer therapies. The partnership includes potential milestone payments exceeding half a billion dollars and tiered royalties.

Noxopharm Limited has been granted its first US patent for the Sofra™ technology platform, marking a key milestone in its cancer immunotherapy research. This patent protects the company’s innovative immune-modulatory oligonucleotides, underpinning its expanding pipeline in a rapidly growing market.

IDT Australia announces a strategic realignment focusing on profitability and operational efficiency, reporting strong revenue growth from its three core verticals and securing $3.4 million in new contracts for FY26.

Invion Limited has partnered with Protect Animal Health to explore Photosoft™, a novel photodynamic therapy, as a treatment for cancer in companion animals, targeting a booming pet cancer market.

PYC Therapeutics has kicked off a global Phase 1b repeat dose study of its investigational drug PYC-001 targeting Autosomal Dominant Optic Atrophy, a rare genetic eye disease with no current treatments. Initial dosing has begun, with key data expected in the second half of 2026.

Neurizon Therapeutics has been granted a key Australian patent for its lead drug candidate NUZ-001, extending protection for treatments targeting ALS, Alzheimer's, and other neurodegenerative diseases through 2041. This milestone complements earlier US patent grants and sets the stage for upcoming clinical trials.

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.

AdAlta Limited has raised up to A$1.1 million through a private placement, boosting its war chest to advance innovative cellular immunotherapy projects targeting solid cancers.